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a b s t r a c t
The H9N2 avian inﬂuenza virus (AIV) has become increasingly concerning due to its role in severe
economic losses in the poultry industry. Transmission of AIV to mammals, including pigs and humans,
has accelerated efforts to devise preventive strategies. To develop an effective oral vaccine against H9N2
AIV, a recombinant Lactobacillus plantarum NC8 strain expressing the hemagglutinin (HA) gene of H9N2
AIV was constructed in this study. Mice were orally immunized with the recombinant NC8-pSIP409-HA
strain, and sIgA, IgG and HI antibodies were produced by the NC8-pSIP409-HA strain, which also induced
CD8þ T cell immune responses. Most importantly, oral administration produced complete protection
against challenge with mouse-adapted H9N2 virus. These results indicate that the recombinant NC8-
pSIP409-HA was more effective at inducing the mucosal, humoral and cellular immune responses.
Therefore, L. plantarum NC8-pSIP409-HA could become a promising oral vaccine candidate against
H9N2 AIV.
& 2014 Published by Elsevier Inc.
Introduction
Low pathogenic avian inﬂuenza (LPAI) H9N2 viruses have
circulated widely around the world and have been isolated from
terrestrial poultry worldwide (Chen et al., 2003; Rahman et al.,
2011; Xu et al., 2007b). Since the outbreak of LPAI H9N2 in 1996
(Lee et al., 2000), the virus has infected a high proportion of
chickens and other land-based birds such as pigeons, pheasants,
quails, chukkas and turkeys (Coman et al., 2013; Guan et al., 2000).
It has received considerable attention because LPAI H9N2-infected
chickens are vulnerable to secondary infection with pathogenic
microbes, which may cause serious commercial economic losses in
the poultry industry (Rahman et al., 2011). More seriously, chick-
ens infected with LPAI H9N2 viruses not only can serve as a
reservoir host but also can transmit the virus to mammals such as
cats, dogs, pigs and people (Alexander, 2000; Blair et al., 2013;
Choi et al., 2004; Coman et al., 2013; Peiris et al., 2001; Webster
et al., 1992). Moreover, H9N2 viruses were also found in patients
with inﬂuenza-like symptoms in southeast China and Hong Kong
SAR (Peiris et al., 1999). In addition, viruses isolated from humans,
such as A/HongKong/1073/1999 and A/Hong Kong/33982/2009,
had the highest risk potential. However, the A/swine/Hong Kong/
9A-1/1998 and A/chicken/Hong Kong/G9/1997 viruses also dis-
played several features that suggested a proﬁle that was adapted
to human infection and transmission (Group, 2013). Importantly,
the six internal genes of novel H7N9 viruses were derived from
LPAI H9N2 (Gao et al., 2013; Liu et al., 2013). LPAI H9N2 viruses
comprise a genetically diverse population that infects wild species
and mammals; they contributed the internal gene segments to the
A/H7N9 viruses associated with lethal human infections, and
different H9N2 strains have different ecological proﬁles and risks.
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These cases indicate that there is an urgent need to control or
prevent the occurrence of LPAI H9N2 disease.
Although vaccination will not solve all of these problems, it is
one of the most promising control measures for the LPAI H9N2 to
date (Rahman et al., 2011). Side effects of the commercialized
vaccines (attenuated and inactivated vaccines) are not uncommon.
For instance, attenuated immunization is an effective antiviral
approach; however, there is a risk of spreading the virus and
reacquiring its toxicity (Perelberg et al., 2005). Compared to the
attenuated vaccines, inactivated vaccines exhibit increased safety
and reduced risk of spreading the disease (Li et al., 2012). Never-
theless, the low immunological protection, instability and the need
for repeated immunization measures make these vaccines less
desirable. In addition, new vaccine preparations, including various
DNA vaccines (Wei et al., 2008), subunit vaccines (Chen et al.,
2008) and recombinant adenovirus vaccines (Gao et al., 2006)
have been examined, but they all require injections, which would
be extremely difﬁcult to perform on wild birds or farm animals.
Moreover, the intense stress caused by injection could hamper
animal growth (Lee et al., 2006; Wang et al., 2006). Based on these
factors, many investigators are pursuing more safe, economical,
convenient and efﬁcacious avenues for constructing new vaccine
candidates to control LPAI H9N2 disease.
Compared with other new vaccines, oral vaccines cause less stress
among animals and have been receiving growing interest due to their
advantages over the conventional parenteral vaccines (Wang et al.,
2012). The greatest advantage is that these vaccines can trigger
mucosal and systemic immune responses against foreign microbial
infection via activated dendritic cells (DCs) (Mohamadzadeh et al.,
2009; Sim et al., 2008), which migrating to the mesenteric lymph
nodes (MLNs) and presenting processed antigens to T and B lymph
cells. Lactobacillus is a genus of gram-positive facultative anaerobic or
microaerophilic rod-shaped bacteria (Wang et al., 2012). These bac-
teria are the commonly members of the gut commensal community
and are among the earliest inhabitants of the gastrointestinal tract
without causing disease (Von Ossowski et al., 2013). Characteristically,
such bacteria have been shown to have a strong propensity to help
promote good health as well as alleviate a variety of health problems
(Dicks and Botes, 2010; Doron and Gorbach, 2006; Tannock, 2004),
and they are therefore generally regarded as safe (GRAS) (Lei et al.,
2010). This approach has been reported in the use of recombinant
lactobacilli to express exogenous antigens for oral administration (Cho
et al., 2010; Gilbert et al., 2000; Robinson et al., 1997; Xin et al., 2003),
both in terms of the amount of antigen expression and the duration of
persistence in the gut (Klijn et al., 1995).
In the present study, we constructed the recombinant NC8-
pSIP409-HA based on Lactobacillus plantarum NC8 expressing
hemagglutinin (HA) of the H9N2 virus. We researched the immuno-
genicity of the recombinant NC8-pSIP409-HA in BALB/c mice with
respect to the induction of hemagglutination inhibition (HI) anti-
bodies as well as HA-speciﬁc serum IgG antibodies, HA-speciﬁc
mucosal IgA antibodies, IFN-γ-producing CD8þ T cells and CD8þ
T cells responses. The protective efﬁcacy of the recombinant NC8-
pSIP409-HA against a homologous virus challenge was determined
by quantiﬁcation of the H9N2 virus in the lungs of BALB/c mice, and a
mouse-adapted H9N2 strain of enhanced pathogenicity was applied
to evaluate the efﬁcacy of the recombinant NC8-pSIP409-HA in
promoting the percent survival.
Results
HA expression by recombinant L. plantarum NC8
pSIP409-HA (Fig. 1A) and pSIP409 were constructed and
introduced into L. plantarum NC8 by electroporation. The cell
lysates of overnight cultures of NC8-pSIP409-HA or NC8-pSIP409
in basal MRS medium with additional SppIP obtained by centrifu-
gation were subjected to SDS-PAGE and western blotting for
examination of the protein expression. An immunoreactive 62-
kDa band was detected in the cell lysates (Fig. 1B, lane 1), whereas
no band was observed in the negative control lane (Fig. 1B, lane 2).
These results showed that HA was expressed by SppIP in
L. plantarum NC8.
HI titers in the sera of mice immunized with recombinant
L. plantarum NC8
The antibody titers in the sera 21, 35 and 49 days after the ﬁrst
immunization were analyzed using an HI assay. As shown in Fig. 2,
antibody titers were not detected after immunization with the
negative control PBS and NC8-pSIP409, whereas antibody titers
increased gradually after immunization with NC8-pSIP409-HA.
In addition, the antibody titers produced by the H9N2 inactivated
vaccine were tested, but there was no signiﬁcant difference
between NC8-pSIP409-HA and H9N2 inactivated vaccines on
day 49.
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Fig. 1. Plasmids for the expression of recombinant hemagglutinin antigen, western
blots of expressed NC8-pSIP409-HA and NC8-pSIP409 proteins and vaccination
schedule. (A) The pSIP409-HA plasmid was constructed as described in the text.
The plasmid structure of pSIP409-HA (7.2 kb). HA: hemagglutinin gene; 256rep:
replication origin for Lactobacillus; ermL: erythromycin-resistance marker; PsppIP
and PorfX: inducible promoters; sppK and sppR: histidine protein kinase and
response regulator, respectively. (B) The HA protein expressed in NC8-pSIP409-HA
was detected by western blotting. M: pre-staining marker, Lane 1: NC8-pSIP409-
HA, lane 2: NC8-pSIP409 as the negative control, lane 3: H9N2 virus as positive
control. (C) Groups of mice were immunized with NC8-pSIP409-HA, NC8-pSIP409
(109 CFU in 200 μl), PBS (200 μl) or H9N2 inactivated vaccine. Immunization via the
oral route was repeated thrice weekly. Two weeks later, the groups of mice were
boosted twice. Six weeks after the ﬁnal boost, the mice were challenged i.n. with
mouse-adapted H9N2 virus. H9N2 inactivated vaccine was injected intramuscularly
on the ﬁrst day. Survival was then monitored until day 14.
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Ab titers against the HA antigen
To evaluate the immunogenicity of the recombinant NC8-
pSIP409-HA, groups of mice were orally immunized, and antibody
titers were determined 21, 35 and 49 days after the ﬁrst immu-
nization. HA-speciﬁc IgA levels in the feces and bronchoalveolar
lavage ﬂuids (BALF) were detected using ELISA. The group immu-
nized with NC8-pSIP409-HA showed relatively high HA-speciﬁc
IgA production in the feces and BALF, whereas the NC8-pSIP409
and PBS showed little speciﬁc IgA production (Fig. 3A and B).
In addition, there was no signiﬁcant difference between NC8-
pSIP409-HA and H9N2 inactivated vaccine. We also detected
signiﬁcant levels of speciﬁc IgG in the serum of mice in the NC8-
pSIP409-HA group (Fig. 3C); the NC8-pSIP409 and PBS produced
no meaningful results regarding antibody (Ab) titers against the
HA antigen. In addition, the current AIV inactivated vaccine,
administered in a single intramuscular injection, induced higher
IgG antibody titers.
The Ab response was also associated with the germinal centers
(GC) in the Peyer's patch (PP), MLN and spleens of the immunized
mice. PP, MLN cells and splenocytes were removed from the four
groups of mice 7 days after the ﬁnal immunization. PP, MLN and
splenocytes were gated on B220þ cells, and staining for the
presence of PNAþ and FASþ B cells was performed. Mice that
were orally immunized with NC8-pSIP409-HA developed signiﬁ-
cant numbers (25.1% of the total isotype-switched B cells) of FASþ
PNAþ B220þ B cells in the PP compared with other groups.
In addition, the H9N2 inactivated vaccine also produced signiﬁcant
numbers (28.6% of the total isotype-switched B cells) of FASþ
PNAþ B220þ B cells in PP. However, there is no signiﬁcant
difference between NC8-pSIP409-HA and H9N2 inactivated vac-
cine. Interestingly, there were also a signiﬁcant number of FASþ
PNAþ B220þ B cells in the MLN and spleens of mice that were
immunized with NC8-pSIP409-HA compared with other groups
(Fig. 3D). The results indicated that GC was formed after oral
immunization. In addition, BALB/c mice immunized with PBS and
NC8-pSIP409 failed to show signiﬁcant numbers of FASþ PNAþ
B220þ B cells. These results indicate that mice that were immu-
nized with NC8-pSIP409-HA demonstrate an effective B cell
response.
Cell-mediated immune responses
Cellular immune responses to NC8-pSIP409-HA were evaluated
by measuring IFN-γ secretion in murine MLN cells and spleno-
cytes. Twenty-one days after the ﬁnal immunization, MLN cells
and splenocytes were harvested from each immunization group,
and the number of IFN-γ-secreting MLN cells and splenocytes was
calculated as the average number of spots in the triplicate
stimulant wells. As shown in Fig. 4A and B, a signiﬁcant number
of HA-speciﬁc IFN-γ-secreting MLN cells and splenocytes
were detected in the immunized group compared with the
control group.
We next investigated the role of activated T cells in the immune
response. Twenty-one days after the ﬁnal immunization, MLN cells
and splenocytes were harvested from each immunization group,
and IFN-γ-producing T cells were analyzed by ﬂow cytometry. The
results show that there was a signiﬁcant increase in the frequency
of IFN-γ-producing CD8þ T cells in the MLN and splenocytes of
mice immunized with NC8-pSIP409-HA. However, IFN-γ-
producing T cells were induced at low levels in mice that were
vaccinated with the H9N2 inactivated vaccine (Fig. 4C). In addition,
the frequency of IFN-γ-producing CD4þ T cells was not meaningful
(data not shown).
T cell proliferation in response to AIV HA antigen restimulation
To test the splenocyte proliferative response upon antigen
restimulation, we measured CD8þT cell proliferation in response
to AIV HA antigen restimulation. Splenocytes were prepared from
mouse spleens 30 days after the booster immunization and were
stimulated in vitro with AIV HA. After 3 days of incubation, the
CFSE proﬁles of CD8þ gated T cells were detected using ﬂow
cytometry. As shown in Fig. 5, when stimulated with AIV HA, cells
isolated from the spleens of mice that were orally administered
NC8-pSIP409-HA displayed signiﬁcant CD8þ T cell proliferation in
response to AIV HA antigen restimulation. However, splenocyte
proliferation was induced at low levels in mice that were vacci-
nated with the H9N2 inactivated vaccine. These results showed
that immunization with NC8-pSIP409-HA elicited a more efﬁcient
and robust splenocyte proliferation response against AIV HA
antigen.
Protection against a lethal challenge with mouse-adapted
H9N2 inﬂuenza virus in mice with the oral administration
of NC8-pSIP409-HA
To determine whether NC8-pSIP409-HA provides protection
against H9N2 inﬂuenza viruses, six weeks after the ﬁnal immuni-
zation, the mice were intranasally challenged with a lethal dose
(10 LD50) of mouse-adapted H9N2 inﬂuenza virus and were
closely monitored for 14 days for weight loss, mortality and lung
virus titer. After the viral challenge, all mice experienced body
weight loss (Fig. 6A), but the mice that were immunized with NC8-
pSIP409-HA gradually recovered after 7 days, and 100% survival
was achieved. In contrast, mice immunized with PBS and NC8-
pSIP409, all died within 10 days of the viral challenge (Fig. 6B). The
AIV inactivated vaccine, administered in a single intramuscular
injection, completely protected the mice from the lethal viral
challenge with mouse-adapted H9N2 inﬂuenza virus (Fig. 6B).
In addition, the residual lung virus titers of the mice that were
immunized with NC8-pSIP409-HA and challenged with the H9N2
viruses were signiﬁcantly lower than the mice in the control
groups (po0.001), as shown in Fig. 6C.
Protection against severe lung pathology in BALB/c mice
To evaluate vaccine efﬁcacy, mice from different groups were
killed, and their lungs were examined microscopically. The results
indicated that BALB/c mice that were orally vaccinated with
NC8-pSIP409-HA and H9N2 inactivated vaccine did not develop
the apparent inﬂammatory changes after challenge with the
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Fig. 2. Antibody levels analyzed using an HI assay. Twenty-one, 35 and 49 days
after the mice were immunized with NC8-pSIP409-HA, NC8-pSIP409, PBS and a
positive control, HI titers were assessed using an HI assay with the H9N2 AIV and a
positive serum antibody. nStatistically signiﬁcant differences relative to the PBS and
NC8-pSIP409 controls (nnnpo0.001). Data are expressed as the mean7SEM of
triplicate experiments. n¼5 mice per group.
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mouse-adapted H9N2 AIV virus, but there was a small number of
mononuclear cells detected by HE staining of the H9N2 inactivated
vaccine (Fig. 7). On the contrary, the lungs developed alveoli with
interstitial edema, a foamy exudate and a large number of mono-
nuclear cells (focal emphysema), and a large number of alveolar
structures were destroyed by oral vaccination withNC8-pSIP409
and PBS (Fig. 7). These ﬁndings show that prophylactically admi-
nistered NC8-pSIP409-HA confers protection against the mouse-
adapted H9N2 challenge and reduces pulmonary pathology.
Discussion
The H9N2 inﬂuenza virus affects humans and can result in an
economically important disease in poultry; therefore, many
researchers are actively pursuing the development of safe and
efﬁcacious oral vaccines, which can be produced economically and
conveniently administered. Wild-type H9N2 avian inﬂuenza virus
A/duck/Xuzhou/07/2003(H9N2) isolated from duck that unin-
fected mice, it was adapted to growth in mice that can infect mice
and result in dying. In this paper, adaptation of wild-type H9N2
virus was model virus that can evaluate the protective rate of the
vaccine in a mouse model. The initial infection with inﬂuenza virus
mainly occurs at the respiratory tract mucosa, which is the site of
defense against virus infection and is a critical step in the infection
process (Tamura and Kurata, 2004). Therefore, mucosal adminis-
tration is the ﬁrst choice for vaccination as an effective prophy-
lactic method against H9N2 AIV. Mucosal vaccines can induce
mucosal immune responses as well as systemic responses, but the
current commercialized vaccines can not induce mucosal immune
responses. In this regard, most investigators are currently focused
on the development of appropriate mucosal vaccines for oral
administration.
The use of recombinant vaccines has been documented for
inﬂuenza viruses previously (Wei et al., 2008; Lee et al., 2006).
Indeed, bacterial and viral vectors expressing HA from H9N2 and
H5N1 avian inﬂuenza have been shown to induce protective
immunity. (Pan et al., 2009; Gao et al., 2006). These systems
may be more immunogenic or may express stronger immune
responses, but most of them were originally pathogenic strains.
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Fig. 3. HA-speciﬁc antibody titers detected with ELISA and activated B cells detected with ﬂow cytometry. Measurement of HA-speciﬁc immunoglobulin A (IgA) Ab titers in
the feces (A) and BALF (B) after immunization. (C) Measurement of HA-speciﬁc immunoglobulin G (IgG) Ab titers in the serum after immunization. Immunization conditions
are displayed at the bottom. (D) Detection of activated B cells in the germinal centers (GC) of immunized mice using ﬂow cytometry. Representative ﬂow cytometric analyses
of GC B cells among B220þ B cells in the Peyer's patches (PP), MLN and spleen 7 days after the ﬁnal immunization. The % of total cells for the quadrants and the bar graphs
refer only to B220þ cells. Values are the percentages of activated GC B cells (PNAþ FASþ) among the gated B220þ cells. Immunization conditions are shown at the top.
nStatistically signiﬁcant differences relative to the PBS and NC8-pSIP409 controls (nPo0.05, nnPo0.01). Data are expressed as the mean7SEM of triplicate experiments. n¼3
mice per group.
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In contrast, the vectors based on Lacticacid bacteria (LAB) are
considered safe, are convenient and are widely used as a live
vaccine vehicle against various foreign microbes (Peiris et al.,
2001; Xu et al., 2007a); however, these may not be as immuno-
genic for the human immune system. Moreover, many researchers
reported that speciﬁc or memory B cells reactive to H5N1 and
H1N1 HA were indeed present in individuals, strongly suggesting
that the vaccine preferentially activates these memory B cells,
thereby producing a humoral response with neutralizing activity
(Whittle et al., 2014; Li et al., 2012). Further studies of memory B-
cell responses to Lactobacillus-based vaccines and natural chicken
AIV infection are needed.
Grönqvist and his colleagues initiated the development of one-
plasmid inducible expression systems based on promoters and
regulatory genes involved in the production of the class II
bacteriocins sakacin P (spp gene cluster), and they constructed
prototypes of the modular so-called pSIP expression vectors
(Grönqvist et al., 2003). The pSIP-409 vector in this study contains
a promoter element derived from the sakacin P structural gene
with an engineered NcoI site for translational fusion cloning,
which encodes the cognate histidine protein kinase and response
regulator that are necessary to activate this promoter upon
induction by sakacin P and gusA reporter gene (Sørvig et al.,
2005). The target protein expression was completely dependent
on the SppIP induction. In addition, the recombinant LAB vector
was used to produce large quantities of antigens. Although
constitutive expression causes improved immunogenicity, an
inducible expression system can relieve the pressure of the
exogenous proteins on LAB, compared to a constitutive expression
system. LAB may have been able to persist over approximately
6 days, preventing immunotolerance against the target antigen
(Xu et al., 2007c). Thus, to mitigate the metabolic stress on the
host bacteria, inducible promoters were chosen in L. plantarum.
The oral administration of recombinant L. plantarum can induce
secretory IgA antibodies in the respiratory tract, which is the
major target organ of inﬂuenza virus infection. Secretory IgA
antibodies are considered a major effector in the adaptive immune
defense of the respiratory mucosa (Underdown and Schiff, 1986).
Although oral administration of L. plantarum or recombinant
Lactococcus lactis protects against inﬂuenza virus infection by
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inducing serum IgG antibodies (Lei et al., 2010) and IgA in the
lungs and bronchoalveolar lavage ﬂuids (BALF) (Kikuchi et al.,
2014; Salva et al., 2010), sublingually administered Lactobacillus
rhamnosus appears to be more effective for inducing protection
against inﬂuenza virus infection, most likely as a result of the high
elicited levels of anti-inﬂuenza virus-speciﬁc IgA in the lungs
(Lee et al., 2013). In this study, the oral administration of recom-
binant L. plantarum NC8-pSIP409-HA can promote the formation
of GCs within the mucosal and systemic sites in mice through
increased numbers of FASþ PNAþ B220þ B cells in the PP, MLN
and spleen. Higher levels of HA-speciﬁc IgA were also produced in
fecal matter and BALF. Such secretory IgA antibody responses
seem to play a role in preventing the entry and replication of the
inﬂuenza virus in the respiratory tract; however, the mechanisms
underlying the reductions in respiratory tract infections and other
symptoms remain unclear.
Glycosylation of viral envelope proteins is very important and
inﬂuences the immunogenicity and the sensitivity of the virus to
neutralizing antibodies. Oligosaccharides may hinder proteolytic
degradation, and with that affect, T-cell recognition by keeping the
appropriate conformation of proteins (Bolmstedt et al., 2001;
Li et al., 2008). Removal of glycans from inﬂuenza viral envelope
proteins has been shown to enhance T cell response (Ertl and Ada,
1981; Wood and Elliott, 1998), and interfere with their immuno-
genicity (Sjölander et al., 1996). Presumably, sugars do not coat HA
in Lactobacillus. In this study, the oral administration of recombi-
nant NC8-pSIP409-HA elicited the strongest cellular immune
response in the MLN and spleen. Glycosylation inﬂuences the
delivery or processing of recombinant proteins for MHC class I
presentation and may block peptide binding to MHC class I
(Haurum et al., 1995). In contrast, the serum IgG titer (Fig. 3C) is
not particularly high compared to many vaccination regimens.
Those phenomena implied that glycosylation of HA is very
important for maintaining the level of humoral immunity. More
importantly, our results support the previous ﬁndings that IFN-γ
producing CD8þ T lymphocytes induce protective immunity
against natural inﬂuenza illness in humans (Sridhar et al., 2013).
IFN-γ is a cytokine that is secreted by T lymphocytes and NK cells
and leads to increased phagocytic activity, which effectively kills
pathogens, modulates chemotaxis and up-regulates antigen pre-
sentation to induce Th1 responses against pathogen challenge
(Schroder et al., 2004). Moreover, it is interesting that CD8þ T cells
have responded to HA 30 days after immunization. These strong
T cell responses may improve the direct lysis of MHC class I-
bearing infected cells (Lu et al., 2011). The effector/memory CD8þ
T cells at mucosal effector sites are notable because they partici-
pate in the initial AIV replication and subsequent viral dissemina-
tion. Most of the results indicated that T cellular immune
responses are considered to play a key role in protecting immunity
against AIV infection in mice.
As shown in Fig. 6, administration of bacteria alone appears to
have improved the survival and weight loss from inﬂuenza
infection. The use of probiotics to combat inﬂuenza has been
shown previously to have some promise in protection against
inﬂuenza. Indeed, oral administration of this bacterial strain
(Lactobacillus planarium) has been shown to increase protection
against inﬂuenza infection by itself (Kikuchi et al., 2014).
In addition, speciﬁc Lactobacillus strains are also supposed to exert
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Fig. 5. Avian inﬂuenza virus (AIV) HA-speciﬁc T cell response to recombinant Lactobacillus plantarum. Splenocytes were isolated 30 days after the ﬁnal immunization, stained
with CFSE and stimulated in vitro with 10 μg/ml of puriﬁed HA protein for 3 days. The data shown are expressed in CFSE histograms of ﬂuorescence intensity versus the
number of ﬂuorescing cells, indicating the percentage of the cell population positive for the CD8 antigen. The values in the ﬁgure are percentages of CD8þ proliferating
T cells. The immunization conditions are displayed at the top. nStatistically signiﬁcant differences relative to the PBS and NC8-pSIP409 controls (nnPo0.01) and to the H9N2
inactivated vaccine (nPo0.05). Data are expressed as the mean7SEM of triplicate experiments. n¼3 mice per group.
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beneﬁcial health properties and are thus intensively studied for
probiotic applications (Dicks and Botes, 2010; Doron and Gorbach,
2006). We therefore choose L. plantarum as a candidate vaccine
vehicle. L. plantarum NC8, our model strain, has been conﬁrmed to
be particularly resistant to the conditions of the upper digestive
tract in mice and chicken. Moreover, we observed that it is able to
persist in the mouse intestine for more than 3–7 days, while
Lactococcus lactis could not be detected in feces 24 h after ending
of the feeding. Interestingly, in this study, the empty vector NC8-
pSIP409 not induce B cell activation, we considered that the result
may be associated with the immunizing doses and procedures, or
the point in time of our detection.
Different vaccines and delivery modes were found to stimulate
different immune responses. Inactivated pathogens, such as for
inﬂuenza, are generally used for pathogens for which a humoral
immune response is considered the primary protective immune
response (Liu, 2010b). Subsequently, gene-based vaccines are able
to deliver heterologous antigens into the antigen-processing path-
ways needed to stimulate MHC class I-restricted CTL responses
(Liu, 2010a). In addition, probiotics-based vaccines are able to
modulate immune stimulatory responses upon interaction with
antigen-presenting cells such as dendritic cells (DCs) and macro-
phages. Several studies that show toll-like receptors (TLRs), play a
key role upon the stimulation of DC and macrophages with
recombinant lactobacilli (Kathania et al., 2013). Furthermore,
exposure to lactobacilli induces the up-regulation of surface
markers and production of several cytokines that modulate the
function of DCs (Christensen et al., 2002; Weiss et al., 2011). It is well
established that high IL-12 production by DCs matured by microbial
stimuli induces Th1 polarization and thus strongly stimulates of the
adaptive immune defense. In this study, the recombinant NC8-
pSIP409-HA was more conducive to the protection of the integrity
of the lungs, compared to the H9N2 inactivated vaccine, which may
be because CD4þ and CD8þ Tregs increased signiﬁcantly in the lungs
of mice that received the oral administration of L. rhamnosus (Lee
et al., 2013). Tregs represent suppressive cell subsets, which act to
regulate T cell responses and are thereby, thought to prevent
pathology resulting from excessive immune responses (Sakaguchi
et al., 2008). These studies imply that probiotics enhance the
activation of helper and cytotoxic T lymphocytes and beneﬁcially
modulate both innate and adaptive immunity.
In conclusion, the present results demonstrated that HA is an
ideal target candidate for the development of vaccines against
H9N2 AIV as previously reported, which can prevent the pandemic
spread of the H9N2 inﬂuenza virus. Similar plans for H9N2
challenges in chickens are in progress pending regulatory
approvals. Future studies are required to consider target AIV
antigens to DC-targeting peptides; studies on AIV vaccination
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Fig. 6. Recombinant NC8-pSIP409-HA protected mice from the mouse-adapted H9N2 AIV infection. Six weeks after the ﬁnal immunization, the animals were challenged
intranasally with a lethal dose (10 LD50) and monitored for weight loss and percent survival. (A) Weight loss (%) of the mice after infection. nStatistically signiﬁcant
differences relative to the PBS and NC8-pSIP409 controls (nPo0.05, nnPo0.01). Data are expressed as the mean7SEM of triplicate experiments. n¼5 mice per group.
(B) Percent survival of mice 0–14 days after infection. nStatistically signiﬁcant differences relative to the PBS and NC8-pSIP409 controls (nPo0.05, nnPo0.01). Data are
expressed as the mean7SEM of triplicate experiments. n¼5 mice per group. (C) For virus titration, lungs were harvested at 5 days after infection and homogenized. The
amount of H9N2 virus in the supernatant was analyzed by TCID50. nStatistically signiﬁcant differences relative to the PBS and NC8-pSIP409 controls (nnnPo0.001). Data are
expressed as the mean7SEM of triplicate experiments. n¼3 mice per group.
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should also address this possibility and determine the protective
effect against heterologous virus challenges that model the natural
exposure to viruses among birds.
Materials and methods
Construction of recombinant NC8-pSIP409-HA expressing HA gene
The Escherichia coli-Lactobacillus shuttle vector pSIP409 and
L. plantarum NC8 (for the delivery of HA protein) were kindly
provided by A.Kolandaswamy (Madurai Kamaraj University, India).
The HA gene fragment (1704 bp) was re-ampliﬁed from previously
constructed pGEM-T-HA following standard PCR conditions using the
primer pairs with KpnI and HindIII restriction sites underlined
(forward primer: 50 CGCGGTACCATGGAAACAATACACTAAT 30, reverse
primer: 50 GGGAAGCTTTTATATACAAATGTTGCATCTGC 30) at their
50 end, respectively. The resulting amplicon was digested with KpnI,
and the 50 termini were blunted using S1 nuclease treatment. The
gene was then digested with HindIII to produce a sticky end at the
30 end. Moreover, the plasmid vector pSIP409 was digested with NcoI
and made blunt using S1 nuclease treatment, followed by digestion
with HindIII to create the respective compatible ends. Puriﬁcation of
the linearized plasmid and the gene fragment were performed using
a gel extraction kit (Axygen). The gene and the plasmid vector were
ligated using a Quick Ligation Kit (Roche) and transformed into E. coli
DH5α (Takara). The clones were conﬁrmed by DNA sequencing using
the primer, 50CGCCCGGTTTAATTTGAAAATTGATATTAGCG30. Finally,
the pSIP409 plasmid and the recombinant pSIP409-HA plasmid were
transformed into L. plantarum NC8 by electroporation as previously
described (Kolandaswamy et al., 2009).
All the L. plantarum NC8 were cultured in De Man, Rogosa and
Sharpe (MRS) medium at 30 1C without shaking. Erythromycin
was used at a concentration of 10μg/ml. E. coli DH5α was cultured
in Luria-Bertani (LB) medium containing 200 μg/ml of ampicillin.
Animals and ethics statement
Pathogen-free female BALB/c mice, aged from 6 to 8 weeks,
were obtained from Beijing HFK Bioscience Co., Ltd., China and
were reared with formulated commercial feed and water provided
ad libitum throughout the whole experimental period. All experi-
mental procedures and animal management procedures complied
with the requirements of the Animal Care and Ethics Committees
of Jilin Agriculture University. The animal facility of the Jilin
Agriculture University is fully accredited by the National Associa-
tion of Laboratory Animal Care.
Immunoblotting
To examine HA antigen expression levels, the recombinant
NC8-pSIP409 and NC8-pSIP409-HA were cultured in MRS broth
supplemented with 10 μg/ml erythromycin. Sakacin P (SppIP) was
added to the culture medium at 0.3 of an OD600 to a ﬁnal
concentration of 50 ng/ml to induce antigen expression. After
induction at 30 1C for 10 h, the bacteria were centrifuged at
5000g for 5 min and resuspended in 1 ml of TBS buffer (0.8%
NaCl, 0.02% KCl, 25mM Tris, pH 7.4) containing 0.1 m Mphenyl-
methylsulphonyl ﬂuoride (PMSF). In brief, the harvested cells
incubated at 30 1C for 5 min and disrupted on ice with sonication.
The protein concentration of the culture lysates was then deter-
mined. Proteins were separated by SDS-PAGE (10% acrylamide)
and transferred to nitrocellulose membranes. The presence of the
HA protein was detected using monoclonal mouse anti-HA anti-
body followed by afﬁnity-puriﬁed horseradish peroxidase (HRP)-
conjugated rabbit anti-mouse immunoglobulin G (Sigma). Visua-
lization of the immunobinding was conducted by enhanced
chemiluminescence (ECL) using an ECL Plus detection kit (Thermo
Scientiﬁc).
Virus and homologous recombination HA protein
A H9N2 avian inﬂuenza virus A/duck/Xuzhou/07/2003(H9N2)
was propagated in the allantoic cavity of 9-day-old chicken eggs.
The allantoic ﬂuid was harvested 72 h after inoculation, and virus
in the allantoic ﬂuid was titrated using a standard hemagglutina-
tion test as previously described (Hirst, 1942). The homologous
rHA was from A/duck/Xuzhou/07/2003(H9N2) that has been
expressed and puriﬁed in the company (Sino Biological Inc.) and
used in all antibody and T cell assays.
NC8-pSIP409-HA H9N2 inactivated vaccine
Normal                        PBS NC8-pSIP409
Fig. 7. Histopathological analysis of lungs in mice challenged with mouse-adapted H9N2 AIV. The mice were euthanized and the lung tissue samples were excised, ﬁxed in
10% neutral buffered formalin and embedded in parafﬁn at 5 days post-challenge with the H9N2 viruses. Tissue sections were stained with hematoxylin and eosin
(magniﬁcation, 100).
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Adaptation of wild-type H9N2 virus to increase virulence in mice
Wild-type H9N2 virus (A/duck/Xuzhou/07/2003) was adapted
to growth in mice using a published protocol (Ilyushina et al.,
2010). Brieﬂy, female 8-week-old BALB/c mice were inoculated
intranasally under sodium pentobarbital with virus. The lungs
were harvested after 2 days and homogenized, and 50 μl of the
centrifuged homogenate was used to inoculate the next passage.
After a total of 9 passages, the virus present in the lung homo-
genate was passaged once in the allantoic cavities of 9-day-old
chicken eggs at 37 1C for 72 h to prepare a virus stock.
Immunization and challenge
Eighty BALB/c mice were randomly divided into four groups.
Four groups of mice were orally immunized with NC8-pSIP409-
HA, NC8-pSIP409 and PBS by using oral gavage and H9N2
inactivated vaccine (Weike Biotechnology) as the positive control
(intramuscular injection with 50 ml/mouse). Brieﬂy, NC8-pSIP409-
HA and NC8-pSIP409 were cultured at 30 1C in MRS broth
supplemented with erythromycin (10 mg/ml) and SppIP (50
ng/ml) for 18 h in tightly capped ﬂasks without shaking. Freshly
cultured bacteria were harvested, washed twice with PBS and
suspended in 200 ml of PBS containing 1109 cfu per mouse.
Administration via the oral gavage was repeated three times on
a weekly basis throughout the study and the groups of mice were
boosted twice two weeks later. Blood was drawn on days 21, 35
and 49 for antibody analyses. Six weeks after the ﬁnal immuniza-
tion, groups of BALB/c mice were challenged intranasally (i.n.)
with 10 LD50 of mouse-adapted H9N2 virus under anesthesia
induced intraperitoneally (i.p.) with 100 ml of 15 mg/ml Mebubar-
bital (Avertin; Sigma). Mice challenged with mouse-adapted H9N2
virus were monitored for 14 days with weight checks every day.
For virus titration in the lung, viruses were inoculated into MDCK
cells and cultured for 3–5 days, and TCID50 values were measured
as previously described (Bai et al., 2011). The experiments were
carried out at least thrice.
HI assay
Hemagglutination inhibition (HI) antibody titers in the sera
were determined using chicken erythrocytes and a standard HI
microtiter assay as previously described (Haan et al., 2001). The HI
titers were deﬁned as the highest serum dilution capable of
preventing hemagglutination.
Sampling from BALF and feces
BALF was obtained as previously described (Grangette et al.,
2001). In brief, BALF was obtained postmortem by inserting a
nylon cannula into the exposed trachea, which was tied in place.
A hypodermic needle and syringe were attached and used to inject
and withdraw 400 ml of 1 mM PMSF (Roche Diagnostics, Rotkreuz,
Switzerland) in PBS thrice. The ﬂuid samples were retained on ice
before centrifugation at 4000g for 20 min at 4 1C, and the super-
natants were then stored at 20 1C until analysis.
Fresh fecal samples were collected from groups of mice; 0.2 g
fecal pellets were added to 1 ml PBS containing 1% BSA and 1 mM
PMSF. After incubation at 4 1C for 12 h, the tubes were vortexed
to disrupt all solid material and then centrifuged at 16,000g for
10 min. The supernatants were collected and stored at 20 1C
until tested.
Ab assays
To detect the amount of each IgA and IgG Ab against HA, we
carried out a protocol described previously based on the enzyme-
linked immunosorbent assay (ELISA) (Haan et al., 2001). Brieﬂy,
96-well polystyrene microtiter plates were coated with 1 μg of
rHA (Sino Biological Inc.) using carbonate-bicarbonate buffer (pH
9.6) and incubated overnight at 4 1C. The plates were washed
thrice with washing buffer (15 mM PBS containing 0.1% Tween 20;
PBST) and blocked with blocking buffer (3% bovine serum albumin
(BSA) in PBST) at 37 1C for 1 h. The serum samples were added at
two-fold dilutions from 1/2 to 1/1024 in wash buffer and incu-
bated at 37 1C for 1 h. Following the incubation, the plates were
washed four times with PBST, and anti-mouse-HRP conjugate
(Southern Biotech) was added to all the wells at a dilution of
1:8000 and incubated for 1 h. After washing four times with wash
buffer, the plate was developed with 0.02% O-phenylenediamine
and 0.015% H2O2 (Zymed) in substrate buffer (15 mM citrate buffer
pH 5.6), and the reaction was stopped after 10 min with 2N H2SO4.
The absorbance was read at 492 nm. End point titers were deﬁned
as the highest dilution that gave an absorbance thrice higher than
background for serum samples or twice for fecal and BALF
samples.
Preparation of single-cell suspensions from PPs, MLNs and spleen
PP cells were separated from groups of mice using a published
protocol (Kikuchi et al., 2014). Brieﬂy, BALB/c mice were sacriﬁced
by cervical dislocation after immunization. PP cells were collected
from the side of the small intestine and incubated in RPMI 1640
(Sigma-Aldrich, St. Louis, MO, USA) with 10% FCS (Sigma-Aldrich)
and 0.2 units of collagenase type I (1 mg/ml; Sigma-Aldrich) with a
magnetic stirrer at 37 1C for 60 min. The cell suspensions were
then passed through a 70-μm nylon cell strainer (BD Biosciences,
San Jose, CA, USA), centrifuged at 4 1C for 5 min and washed with
PBS. Then, they were vigorously shaken for 10 s and centrifuged at
4 1C for 5 min. After washes, the cells were incubated in FACS
buffer for staining.
MLNs cells and splenocytes were isolated by gentle crushing of
organs through a 70 mM pore ﬁlter (BD Falcon). Splenocytes were
further treated with ACK lysis buffer (BD Pharm LyseTM) to lyse red
blood cells (RBCs), and the cell suspensions were washed and
resuspended in complete RPMI 1640.
Flow cytometry
Flow cytometry was carried out as described previously
(Lu et al., 2011). In brief, single cell suspensions from immunized
mice were blocked with CD16/CD32 (2.4G2, BD Pharmingen) and
washed in ﬂuorescence activated cell sorting (FACS) buffer (PBS, 1%
FCS, 0.09% sodium azide). The cells were analyzed for B cell
activation by staining with phycoerythrin (PE)-conjugated anti-
bodies for B220 (clone RA3-6B2, BD Pharmingen), PE-Cy7-
conjugated antibodies for Fas (clone Jo2, BD Pharmingen) and
ﬂuorescein isothiocyanate (FITC)-conjugated peanut agglutinin
(PNA, Sigma). After staining, the samples were examined with a
BD FACS Calibur (BD Biosciences), and the data were analyzed by
using FlowJo 7.6.1 software.
Intracellular cytokine staining
To estimate cytokine-producing cells, intracellular cytokine
staining (ICS) was performed as previously described (Lee et al.,
2007). Brieﬂy, MLN and spleen lymphocytes from the different
groups of mice were isolated after booster vaccination and
incubated for 8 h with HA antigen (10 μg/ml) or medium alone.
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The cells were then cultured for another 4 h in the presence of
monensin (10 μg/ml; BD GolgiStop™ protein transport inhibitor).
The cells were washed and stained with PerCP-Cy5.5-conjugated
antibodies for CD3e (clone 145-2C11), APC-Cy7-conjugated anti-
bodies for CD8 (clone 53-6.7) (BD Pharmingen). The cells were
then washed, ﬁxed and permeabilized with the Cytoﬁx/Cyto-
perm™ Plus Fixation/Permeabilization kit (BD Pharmingen)
according to the manufacturer's instructions. Finally, cells were
stained with either APC-conjugated anti-IFN-γ (clone XMG1.2) or
isotype control APC conjugated antibodies (BD Pharmingen). The
cells were examined using BD FACS CantoTM ﬂow cytometry.
T cell proliferation assay
T cell proliferation in response to HA antigen was evaluated as
described previously (Lu et al., 2011). In brief, carboxyﬂuorescein
diacetate succinimidyl ester (CFSE, Invitrogen) was added to
splenocyte suspensions by immunizing mice with107/ml in pre-
treated PBS (37 1C) containing 0.1% BSA to a ﬁnal concentration of
2 μM. The reaction mixtures were then incubated for 15 min at
37 1C. Then, cold FBS was added and incubated on ice for 10 min to
stop the reaction, and the samples were washed thrice with RPMI-
1640 containing 10% FCS. After labeling with CFSE, the splenocytes
(5105) were plated into 96-well plates and cultured in 200 μl of
complete RPMI medium with or without HA (10 μg/ml; Sino
Biological Inc.), anti-CD3 (0.1 μg/ml) plus anti-CD28 (2 μg/ml) as
a positive control. After 3 days, the cells were collected and stained
with PE-Cy7-conjugated antibodies for CD4 (clone GK1.5) and
APC-Cy7-conjugated antibodies for CD8 (clone 53-6.7), and then
analyzed by BD FACS CantoTM ﬂow cytometry.
IFN- γ ELISpot assay
The IFN-γ ELISpot assay was performed 21 days after the ﬁnal
immunization using an ELISpot kit for mouse IFN-γ as recom-
mended by the manufacturer (Mabtech). Brieﬂy, ﬁrst the mem-
brane of the ELISpot plate was pre-wetted by adding 50 μl 70%
ethanol per well in sterile conditions. The mouse IFN-γ plate was
ﬁlled with 200 μl/well of sterile culture media and incubated for at
least 30 min at room temperature. After aspirating the culture
media from the wells, 100 μl of 5105 splenocytes and MLN cells
were added per well. HA protein (10 μg/ml) was used as stimuli in
a 37 1C humidiﬁed incubator with of 5% CO2 for 48 h. Control wells
were not stimulated with HA protein. After incubation, each well
was aspirated and washed, the plates were treated sequentially
with biotinylated monoclonal anti-mouse IFN-γ antibody,
streptavidin-horseradish peroxidase and the substrate solution to
reveal the spots. The developed microplate could be inspected by
counting spots in an ELISpot reader (AID).
Histopathological examination
To assess pulmonary inﬂammation after mouse-adapted H9N2
virus infection, mouse lungs were isolated from each group and
immediately placed in a 10% neutral buffered formalin ﬁxative. The
tissues were then processed and embedded in parafﬁn. Slides were
then cut, the sections were stained with hematoxylin and eosin to
visualize cellular inﬂammation, and the samples were read blindly.
Statistical analysis
All results are expressed as geometric mean titers with mean of
at least three independent experiments. Statistical signiﬁcance
was determined using unpaired two-tailed t tests. GraphPad Prism
5 software was used for the statistical analyses.
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